This approach of increasing anti-PD-1 efficacy has been validated in pre-clinical experimental models in metastatic melanoma and renal cell carcinoma through modulating PD-L1 expression downstream of NLRP3 activation [11,44]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.